[P16/Ki-67 dual stain in the triage of PAPIII/IIID cytology in cervical cancer screening]
Kisser A, Zechmeister-Koss I
Record ID 32013000925
German
Authors' objectives:
Cervical cancer screening has effectively reduced incidence and mortality from invasive cancer in Austria. Each year however several thousands of healthy women undergo extensive diagnostic procedures following equivocal results in the cytologic evaluation of cervical cells with the PAP test (PAP III or PAP IIID in Austria), as a consequence of the low sensitivity of this screening method. The p16/KI-67 Dual Stain test claims to detect virally induced oncogenic molecular changes in the cell through the immune cytochemical
double staining of the tumour suppressor gene p16INK4a and the proliferation marker Ki-67 and thereby to improve the triage of women with equivocal cytological results in cervical cancer screening.
Authors' recommendations:
The evidence on diagnostic accuracy and clinical utility of the p16/Ki-67 Dual Stain immune cytochemistry is insufficient at present to support inclusion of the test in the benefits catalogue. Further clinical studies demonstrating the clinical utility of the test are indicated.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://eprints.hta.lbg.ac.at/1009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Ki-67 Antigen
- Mass Screening
- Neoplasm Grading
- Uterine Cervical Neoplasms
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.